Serum IL-18/IL-13 Ratio Predicts Super Response to Secukinumab in Patients with Psoriasis
Open Access
- 3 July 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6432
Abstract
Identifying immunologic predictors of clinical responses remains an unmet need in the era of biologic therapy for psoriasis. Super responders (SRs), defined as patients achieving complete skin clearance within weeks of treatment initiation, represent an emerging clinical endotype; however, their immunological profiles remain insufficiently characterized. We conducted a prospective observational study to characterize serum cytokine profiles associated with SR status in biologic-naïve patients with moderate-to-severe plaque psoriasis treated with secukinumab, an IL-17A inhibitor. Twenty-eight patients were enrolled and stratified at week 12 into SR (PASI = 0; n = 9) and non-super responder (NSR; PASI > 0; n = 19) groups. Serum concentrations of 19 cytokines were analyzed at baseline and after 12 weeks of treatment. SRs displayed a distinct immunological signature characterized by significantly higher IL-13 and lower IL-18 baseline levels compared to NSRs (p = 0.002 and p = 0.007, respectively), alongside reduced baseline monocyte counts. L1-regularized logistic regression confirmed IL-13 and IL-18 as strong independent predictors of SR status (AUC = 0.91). Moreover, the IL-18/IL-13 ratio emerged as a highly discriminative biomarker (p = 0.00001, AUC = 0.86). Notably, SRs exhibited a more pronounced decline in IL-18 and IL-23 during treatment. Our findings provide novel insights into the immunopathogenesis of super response and suggest that an immunological milieu favoring Th2 polarization may promote superior outcomes with IL-17A blockade. Incorporating IL-13, IL-18, and their ratio into clinical algorithms may facilitate precision-guided biologic therapy in psoriasis.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective StudyDermatology and Therapy, 2025
- Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-yearJournal of Dermatological Treatment, 2024
- How to define a ‘super-responder’ to biologics in psoriasis studiesBritish Journal of Dermatology, 2023
- Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World StudyClinical Drug Investigation, 2021
- The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis PathogenesisClinical Reviews in Allergy & Immunology, 2018
- The IL-23–IL-17 immune axis: from mechanisms to therapeutic testingNature Reviews Immunology, 2014
- A Single Intradermal Injection of IFN-γ Induces an Inflammatory State in Both Non-Lesional Psoriatic and Healthy SkinJournal of Investigative Dermatology, 2012
- Interleukin-18 Levels in the Plasma of Psoriatic Patients Correlate with the Extent of Skin Lesions and the PASI ScoreActa Dermato-Venereologica, 2003
- Interleukin-13 Receptor in Psoriatic Keratinocytes: Overexpression of the mRNA and Underexpression of the ProteinJournal of Investigative Dermatology, 2002
- Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12Immunity, 2000